Lantheus Holdings, Inc. — Form SCHEDULE 13D
Filed September 4, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 28/100
What the filing says
Lantheus Holdings (filer, North Billerica MA) filed a Schedule 13D on 2026-09-04 regarding Radiopharm Theranostics Ltd (Australian pharmaceutical company, Level 3, 62 Lygon Street Carlton VIC). The filing documents disclose acquisition of beneficial ownership, but the specific share count, percentage stake, dollar amount, and transaction details are not legible in the header metadata provided—only document references are visible.
Why this rating
Schedule 13D filing alone is routine disclosure; significance depends on stake size and transaction value—not stated in accessible text. Without concrete ownership %, deal size, or strategic rationale, cannot assess materiality vs. $4.3B market cap.
See more from September 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.